Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31225278 | 1.00 | KDM4E (0.68) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL6508815 | 0.85 | ALDH1A1 (0.65) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL16216740 | 0.84 | RAB9A (0.50) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL14005479 | 0.82 | KDM4E (0.68) | KDM4EPOLBRAB9AMEN1KMT2A | |
| Limantrafin SCHEMBL25340427 | 0.81 | KDM4E (1.00) | KDM4EPOLBRAB9AMEN1KMT2A | |
| Limantrafin SCHEMBL4638726 | 0.81 | KDM4E (1.00) | KDM4EPOLBRAB9AMEN1KMT2A | |
| SCHEMBL20931739 | 0.81 | KDM4E (0.73) | KDM4EPOLBRAB9AMEN1KMT2A | |
| Limantrafin SCHEMBL21597014 | 0.80 | KDM4E (0.97) | KDM4EPOLBRAB9AMEN1KMT2A | |
| Limantrafin SCHEMBL30617842 | 0.80 | KDM4E (0.97) | KDM4EPOLBRAB9AMEN1KMT2A | |
| Limantrafin SCHEMBL29221528 | 0.80 | KDM4E (0.97) | KDM4EPOLBRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113616648-A | Notch signaling pathway inhibitors and their use in cancer treatment | 洛桑联邦理工学院(EPFL) | 2021-11-09 | — | — | CN | claimed |
| US-11085918-B2 | Method for identifying modulators of notch signaling | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-08-10 | — | — | US | claimed |
| US-20190219566-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2019-07-18 | — | — | US | claimed |
| US-10054581-B1 | Inhibitors of notch signaling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2018-08-21 | — | — | US | claimed |
| US-20180224429-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2018-08-09 | — | — | US | claimed |
| EP-3332783-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2018-06-13 | — | — | EP | claimed |
| EP-2793884-B1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2017-11-29 | — | — | EP | claimed |
| US-9296682-B2 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-29 | — | — | US | claimed |
| EP-3332783-B1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-12030855-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | CELLESTIA BIOTECH AG (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20220388961-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | CELLESTIA BIOTECH AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11472771-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | CELLESTIA BIOTECH AG (CH) | 2022-10-18 | — | — | US | disclosed |
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-12-09 | — | — | US | disclosed |
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-12-09 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2793884-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole Polytechnique Federale de Lausanne (EPFL) (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093885-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013093885-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472771-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | ADH1C, ADH1A, DDC | KDM4E 499/4885POLB 2056/4885RAB9A 932/4885 |
| US-20210382038-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | NOTCH3, NOTCH1, NOTCH4 | KDM4E 338/4885POLB 3703/4885RAB9A 3388/4885 |
| US-20190219566-A1 | METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING | NOTCH3, NOTCH1, NOTCH4 | KDM4E 338/4885POLB 3703/4885RAB9A 3388/4885 |
| US-11085918-B2 | Method for identifying modulators of notch signaling | NOTCH3, NOTCH1, NOTCH4 | KDM4E 338/4885POLB 3703/4885RAB9A 3388/4885 |
| US-10054581-B1 | Inhibitors of notch signaling pathway and use thereof in treatment of cancers | NOTCH1, NOTCH3, NOTCH4 | KDM4E 468/4885POLB 2754/4885RAB9A 3116/4885 |
| US-20140329867-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | NOTCH3, NOTCH1, NOTCH4 | KDM4E 464/4885POLB 2745/4885RAB9A 3103/4885 |
| US-20220388961-A1 | PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS | ADH1C, ADH1A, DDC | KDM4E 499/4885POLB 2056/4885RAB9A 932/4885 |
| US-12030855-B2 | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts | ADH1C, ADH1A, DDC | KDM4E 499/4885POLB 2056/4885RAB9A 932/4885 |
| US-20180224429-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | NOTCH3, NOTCH1, NOTCH4 | KDM4E 464/4885POLB 2745/4885RAB9A 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.